Navigation Links
Nouveau Life Pharmaceuticals (NOUV) to Begin Sales of Azul Instant™
Date:6/6/2012

FORT LAUDERDALE, Fla., June 6, 2012 /PRNewswire/ -- Nouveau Life Pharmaceuticals Inc. (Pink Sheets: NOUV), a provider of quality all-natural dietary supplements, reported today that production is complete on the first run of Azul Instant™, an all-natural male enhancement supplement for erectile dysfunction (ED) that works in 5 minutes and lasts up to 48 hours.

Nouveau Life began production of Azul Instant™ earlier this spring. Manufacturing is complete, and the product is currently being shipped to the warehouse. Nouveau Life anticipates online sales of Azul Instant™ to begin in the next two weeks.

In addition, Nouveau Life has released a complementary product to Azul Instant™ that can be taken daily to help the over 30 million men in the U.S. who suffer with ED. The new supplement Azul: Male Enhancer™ is designed to support a healthy libido in men. Regular use of the supplement Azul: Male Enhancer™ promotes being ready when it counts. Azul: Male Enhancer™ is available for purchase at www.nlpnaturals.com.

"It made sense to us that some men would prefer a daily supplement while some men would prefer a supplement that could be taken only when needed," stated Nouveau Life CEO Melissa Walker. "We are working behind the scenes to get Azul Instant™ on the market as quickly as possible. We know the market has been anxious for the supplement's arrival, as have we. It is the only all-natural ED supplement on the market that works in 5 minutes. In the meantime, we're proud to announce our daily ED supplement Azul: Male Enhancer."

With the addition of Azul: Male Enhancer™, Nouveau Life currently offers three all-natural supplement products. Nouveau Life's signature New Life Naturals™ line includes New Life Naturals: For Her Senses™ intended to help the nearly 48% of American women suffering with female sexual dysfunction (FSD) and New Life Naturals: For Your Weight Loss™, a Raspberry Ketone Formula with Acai designed to aid in safe weight loss for the 36% of Americans classified as obese. All of Nouveau Life's products can be purchased by visiting www.nlpnaturals.com.

About Nouveau Life Pharmaceuticals
The Company, formerly known as Hybrid Fuels, Inc., was incorporated in the state of Nevada in 1998 as Polo Equities. It has primarily been a development stage company with management focused on developing innovative business opportunities and further advancing technologies.

Forward-Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. You should consider these factors in evaluating the statements herein, and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Nouveau Life Pharmaceuticals, Inc. undertakes no obligation to update such statements.

CONTACT:
Nouveau Life Pharmaceuticals, Inc. - 954-903-2993


'/>"/>
SOURCE Nouveau Life Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
2. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)...  True Health, a leader in integrated diagnostics ... National Breast Cancer Awareness month to educate doctors ... Research recently published in ... than 10 million American women are at significant ... BRCA2 and have not had testing. These mutations can ...
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor ... on sciatica in a new episode of "Success Files," which is an award-winning ... innovation and investigates each subject in-depth with passion and integrity. , Sciatica occurs ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
(Date:10/12/2017)... Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... is holding a treadmill relay – Miles by Moonlight to raise money for the ... donating $300 or more. , Teams will work together to keep their treadmills ...
Breaking Medicine News(10 mins):